Aino Health (AINO) Q1 2025 earnings summary

Executive summary

• Revenue increased 23% year-over-year to 7,378 TSEK for Q1 2025, with positive cash flow and EBITDA achieved.

• Profit after financial items improved to -554 TSEK from -2,943 TSEK year-over-year.

• Operational focus on margin improvement and cost reduction is yielding results.

• SaaS subscriber base reached 114,000 at the end of March 2025.

Financial highlights

• Net sales: 7,378 TSEK (Q1 2025) vs. 5,994 TSEK (Q1 2024).

• Operating loss: -420 TSEK (Q1 2025) vs. -2,879 TSEK (Q1 2024).

• Cash flow from operating activities: 504 TSEK (Q1 2025) vs. -749 TSEK (Q1 2024).

• Cash and cash equivalents at period end: 1,081 TSEK.

• Equity ratio: -13% as of March 31, 2025.

Outlook and guidance

• Market conditions expected to gradually improve towards summer and in the second half of 2025.

• Focus remains on operational excellence, customer relationship deepening, and seizing new opportunities.